Skip to main content

EPKINLY Abbvie Pty Ltd

Product name
EPKINLY
Sponsor
Accepted date
Apr-2023
Active ingredients
epcoritamab
Proposed indication
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) .
Application type
A (new medicine)
Publication date
Apr-2023
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.

Help us improve the Therapeutic Goods Administration site